Skip to main content
Daily Report

Daily Cosmetic Research Analysis

01/29/2026
3 papers selected
15 analyzed

Analyzed 15 papers and selected 3 impactful papers.

Summary

Three papers advance cosmetic and dermatologic science from complementary angles: a clinical-ex vivo program shows a wound repair cream can preserve microbiome diversity and speed skin barrier recovery; a supramolecular salicylic acid–betaine complex improves in vitro tolerance while maintaining hydrating pathways; and a consensus-driven review maps and recommends definitions for animal-free “new approach methodologies” to align global cosmetics safety communication.

Research Themes

  • Microbiome-preserving wound care in dermatology
  • Supramolecular design to enhance cosmetic active tolerability
  • Terminology harmonization for animal-free safety assessment (NAMs)

Selected Articles

1. An innovative ecobiological wound repair cream that restores the microbiome.

74.5Level IIICohort
European journal of dermatology : EJD · 2025PMID: 41608923

This multi-platform study shows a wound repair cream can accelerate microbiome diversity restoration after disinfection and enhance re-epithelialization, while improving barrier function in short-term clinical settings. Clinical endpoints (TEWL, erythema, inflammation, skin pH) improved without favoring pathogenic bacteria.

Impact: It integrates microbiome metrics with ex vivo and in vivo efficacy, providing early translational evidence that microbiome-preserving wound care can improve healing outcomes.

Clinical Implications: Supports using microbiome-preserving creams for minor erosions and post-procedural care (e.g., chemical peels) to reduce TEWL, erythema, and inflammation while maintaining commensal balance.

Key Findings

  • Accelerated restoration of skin microbiome diversity after disinfection (+31%, p=0.001).
  • Enhanced wound closure and increased expression of Ki67, loricrin, CD44, and collagens (XVII, VII, III) in a 3D human skin wound model.
  • Short-term clinical improvements: reduced TEWL (day 4 and 7), erythema (day 7), and functional signs of erosions; post-peel reductions in inflammation, visible damage, and skin pH.

Methodological Strengths

  • Triangulation across microbiome analysis, ex vivo 3D wound model, and two clinical studies.
  • Quantitative outcomes with statistical significance (e.g., TEWL, erythema, p-values reported).

Limitations

  • Short-term assessments; longer follow-up and randomized designs are not reported.
  • Sample sizes and detailed clinical protocols are not specified in the abstract.

Future Directions: Randomized controlled trials with longer follow-up to confirm clinical benefits, microbiome durability, and safety; subgroup analyses in post-procedural dermatology.

Small everyday wounds would benefit from optimal healing conditions, and the role of the microbiome in this process is being increasingly discussed. Objectives: To evaluate a wound repair cream (Cicabio Crème+, NAOS Ecobiology Company, Bioderma, France), assessing its effects on the skin microbiome and wound healing. The impact on the microbiome was evaluated by monitoring restoration of diversity after disinfection. The efficacy of the repair complex was assessed ex vivo using a 3D wound-healing human skin model to analyse closure and protein expression. Short-term evaluation of adherence, gas permeability, wound protection, and hydration was assessed. In vivo efficacy was examined through two clinical studies: one on healing erosive areas and another after chemical peel. After disinfection, the cream accelerated restoration of microbiome diversity (+31%, p=0.001) without promoting pathogenic/commensal bacteria or altering the level of Staphylococcus epidermidis (p=0.193). In a 3D wound-healing model, the repair complex enhanced wound closure, promoting protein expression (Ki67, loricrin, CD44, collagen XVII, VII, III) and re-epithelialisation. The cream adhered to the skin, allowed gas exchange, and provided protection and hydration. In vivo, the cream reduced transepidermal water loss (day 4: p=0.016; day 7: p=0.014), erythema (day 7: p=0.023), and functional signs (day 4: p=0.032) of erosive wounds. Following chemical peels, the cream reduced inflammation (day 7: p=0.037), visible damage (day 7: p=0.029), and skin pH (day 1: p<0.001). We demonstrate, for the first time, protection of microbiome diversity, stimulation of wound closure, and preservation of skin pH using a wound repair cream.

2. A Supramolecular salicylic acid - betaine with superior epidermal benefits and better tolerance: in vitro proof of concept studies.

66Level VCase-control
Skin pharmacology and physiology · 2026PMID: 41610079

Supramolecular salicylic acid–betaine retained its crystalline architecture and improved keratinocyte/model viability, reduced inflammatory cytokines, and increased AQP-3 versus SA or SA+betaine physical mixture. Transcriptomics indicated less perturbation of barrier genes (loricrin, LCE) while maintaining HAS upregulation, suggesting better topical tolerance with preserved hydrating effects.

Impact: This mechanistic proof-of-concept links supramolecular formulation to improved tolerance and hydration biology, offering a rational design path for better-tolerated keratolytics in cosmetic dermatology.

Clinical Implications: Supports development of better-tolerated salicylic acid formulations for sensitive or barrier-compromised skin, warranting clinical validation in acne, photo-damage, or hyperkeratotic disorders.

Key Findings

  • Supra SA-B retained supramolecular structure post-processing (PXRD confirmation).
  • Higher cell/model viability and lower inflammatory cytokine release versus SA or SA+betaine physical mixture after 18 hours.
  • Increased AQP-3 and more organized epidermal structure with less adverse impact on loricrin/LCE; HAS upregulation preserved.

Methodological Strengths

  • Head-to-head comparison with SA and physical mixture across multiple readouts (viability, cytokines, histology, IF, RNA-seq).
  • Use of human primary keratinocytes and reconstructed human epidermis to model topical exposure.

Limitations

  • Preclinical in vitro/RHE models without human clinical validation.
  • Short exposure window (e.g., 18 hours) and product concentrations/dose-responses not detailed in the abstract.

Future Directions: Conduct dose-ranging, vehicle-controlled clinical trials in sensitive skin cohorts to confirm tolerability and efficacy; explore broader supramolecular chemotypes for keratolytics.

INTRODUCTION: Recent progress in supramolecule research has led to a surge in its application in cosmetic products. However, comprehensive investigation of the potential benefits, especially differentiating biological activities and associating that with physical-chemical properties, remains to be established. In the current study, a supramolecular salicylic acid-betaine (Supra SA-B) was benchmarked to its physical mixture counterpart for its impact on epidermal homeostasis as well as insult potential when applied topically. METHODS: The structure of supra-SA-B and physical mixture of SA+B (1:1 molar ratio) were characterized by a powder X-ray diffractometer before and after dissolution in aqueous alcohol solution. For skin tolerance evaluation, SA, Supra-SA-B, and SA+B were applied systematically to primary human keratinocytes or topically on the surface of SkinEthic™ RHE reconstructed human epidermal models. Cell and model viabilities were assessed using MTT assay, respectively. Inflammatory cytokines produced by models were assessed using Luminex multi-plex assay. Histological morphology was evaluated by hematoxylin-eosin (HE) staining, with aquaporin-3 (AQP-3) and Ki67 measured by immunofluorescence (IF). Finally, RNA-sequencing was conducted to characterize overall biological response based on non-targeted transcriptomic profiles. RESULTS: Characteristic peaks remained the same for Supra-SA-B after freeze drying verified that their crystalline structures, including supramolecular, were retained in the current solution. With the addition of betaine and introduction of supramolecular format, Supra-SA-B treated groups demonstrated significantly higher cell viabilities comparing to SA or SA+B. With 18-hrs of treatment, Supra-SA-B treated group released less inflammatory cytokines. In addition, Supra-SA-B demonstrated better hydration effect with increased AQP-3 expression and more organized epidermal structure, in comparison to either SA alone or SA+B. Consistent result was observed in the RNA transcriptomic profiles of RHE models after treatment. Supra-SA-B did not induce major transcriptome drift as compared to SA or SA+B, with less evident negative impact on loricrin, and late cornified envelope (LCE) gene expression. At the same time, the boosting effect on hyaluronic acid synthase (HAS) was maintained across all the treatments vs. control. CONCLUSION: Our findings indicated that Supra-SA-B ameliorated skin tolerance risk for SA, enhanced hydration with less insult on barrier functions, suggesting promising potential for cosmetic application.

3. Lost in NAMs-lation: A review of animal-free science definitions.

60.5Level VSystematic Review
ALTEX · 2026PMID: 41609486

This narrative mapping of definitions clarifies inconsistent use of NAMs and ‘animal’ across regulatory and scientific arenas and recommends an ICCS-aligned definition. The work provides tabulated references to standardize terminology, facilitating international collaboration in animal-free cosmetics safety and risk assessment.

Impact: Terminology alignment is foundational for regulatory acceptance and cross-border data sharing of animal-free methods used widely in cosmetics safety.

Clinical Implications: While not directly clinical, clearer definitions of NAMs can accelerate regulatory pathways for safety testing in cosmetics and related dermatologic products, indirectly influencing product availability and ethical standards.

Key Findings

  • Identifies substantial inconsistency in the usage of ‘NAMs’, ‘animal’, and ‘animal-free’ across regulatory, academic, and legal contexts.
  • Proposes a recommended definition of NAMs agreed by the International Collaboration on Cosmetics Safety to guide future alignment.
  • Provides tabulated definitions and sources as a practical reference to improve transparency and global communication.

Methodological Strengths

  • Comprehensive mapping drawing from regulatory, academic, and institutional sources.
  • Actionable output via tabulated definitions and a recommended consensus definition.

Limitations

  • Narrative review without systematic methodology or bias assessment described.
  • Impact depends on adoption by regulators and stakeholders, which is not evaluated.

Future Directions: Convene multi-stakeholder consensus processes to operationalize definitions in guidance documents; evaluate the effect of definition alignment on regulatory decisions and data interoperability.

The use of terminology related to animal-free science has grown rapidly over the past two decades; however, definitions and interpretations of key terms remain inconsistent across global regulatory, scientific, and policy contexts. The term 'new approach methodology(ies)' (NAM(s)) exemplifies this issue: Though rarely used prior to 2020, its uptake in scientific literature has increased substantially in recent years. Despite this growth, the term, and its acronym, 'NAM', is used with varied meanings, leading to misunderstanding regarding the types of methods described. Similarly, the term 'animal' is defined differently across common language, scientific discourse, and legal frameworks, resulting in further ambiguity in what constitutes 'animal-free science'. These variations can hinder productive dialogue and collaboration, particularly in international settings. This manuscript maps the current landscape of definitions of key terms such as 'NAM', 'animal', and 'animal-free', drawing on regulatory, academic, and institutional sources to enhance understanding of the range of existing interpretations. By improving transparency and clarity in terminology, this effort seeks to support more coherent and effective global communication in the field of animal-free science. In addition, the definition of NAM, as agreed by the members of the International Collaboration on Cosmetics Safety, is put forward as a recommendation for future alignment on the term. Tabulated definitions and sources are provided as a reference tool. Over the past 20 years, more people have been talking about animal-free science, but the meaning of key terms like ‘new approach methodology(ies)’ (NAM(s)), or even ‘(protected) animal’ is not always clear. Different people using these terms in different ways can lead to confusion and misunderstandings. This paper looks at how these key terms are currently used and defined around the world. It aims to draw attention to where definitions are similar or different and provides a table as a reference to improve communication and support global collaboration in animal-free science.